SARS-CoV-2 infection in cardiovascular disease: Unmet need of stem cell models.
Luca Anna BorsBarbara OrsolitsNorah Mahnoor AhmedHyunsoo ChoBéla MerkelyGábor FöldesPublished in: Physiology international (2022)
This review aims to summarise new approaches in SARS-CoV-2-related research in cardiology. We provide a head-to-head comparison of models, such as animal research and human pluripotent stem cells, to investigate the pathomechanisms of COVID-19 and find an efficient therapy. In vivo methods were useful for studying systemic processes of the disease; however, due to differences in animal and human biology, the clinical translation of the results remains a complex task. In vitro stem cell research makes cellular events more observable and effective for finding new drugs and therapies for COVID-19, including the use of stem cells. Furthermore, multicellular 3D organoids even make it possible to observe the effects of drugs to treat SARS-CoV-2 infection in human organ models.
Keyphrases
- stem cells
- pluripotent stem cells
- sars cov
- endothelial cells
- respiratory syndrome coronavirus
- cardiovascular disease
- induced pluripotent stem cells
- coronavirus disease
- type diabetes
- cell therapy
- acute kidney injury
- metabolic syndrome
- cardiac surgery
- optic nerve
- cardiovascular risk factors
- coronary artery disease
- bone marrow
- replacement therapy
- clinical evaluation